AeroNeph Therapeutics, Inc. Nominates a Hit-to-Lead STING Inhibitor Small Molecule for In Vivo Studies Focused on Parkinson’s Disease and for Further Development in Autoinflammatory and Autoimmune Disease Indications In studies begun by DiscoveryBioMed, Inc. in collaboration with Nitor Therapeutics, Inc. (Birmingham, AL) and funded by a Phase 1 SBIR grant award, AeroNeph Therapeutics, Inc. (Birmingham, […]
Read More
We are very excited about this publication because it provides proof-of-concept (PoC) that human cell-based drug discovery can identify hit-to-lead compounds in a few key in vitro human cell-based assays that are then proven to work in vivo in the human mouth. Indeed, 6-methylflavone is an example of a panel of flavones that we can […]
Read More
AeroNeph Therapeutics, Inc. Is Developing Novel Lead and Hit-to-Lead Small Molecules Discovered with Unique Diseased Human Cell-based Drug Discovery Designs AeroNeph Therapeutics, Inc. (Birmingham, AL, USA) was founded to continue development of novel lead and hit-to-lead small molecules for a spectrum of human genetic diseases. The discovery work was performed by the parent company, DiscoveryBioMed, […]
Read More
DiscoveryBioMed, Inc. Acquisition by Eurofins Discovery Panlabs Drives the Creation of AeroNeph Therapeutics, Inc. to Continue to Develop Small Molecule Therapeutic Assets for Human Disease Indications The Eurofins acquisition of the CRO services business of DiscoveryBioMed, Inc. is described briefly below. The DiscoveryBioMed, Inc. human cell biology, the human cell models and assays were the […]
Read More